Sales and profits increased due to the expansion of the dispensing pharmacy business, but the bottom line declined due to the impact of the fire at the contract logistics center outsourced by the pharmaceutical manufacturing and sales business. The company expects to record insurance claim income by the end of the current fiscal year.
Sales and profit were up on the back of steady growth in prescription volumes, on top of contributions from 29 pharmacies opened in the previous fiscal year and 30 in the current fiscal year.
Drugs newly listed since FY3/20 drove higher sales. Profit was down due to product recalls over quality issues at Choseido Pharmaceutical and temporary suspension of business operations due to administrative disciplinary action.
Demand has dropped off for vaccination-related work, but the number of doctor placement contracts grew. Sales and operating profit were down due to lower temporary staffing and placements in the pharmacist business.
Despite the impact of COVID-19, sales and profit were up owing to robust performance in the Dispensing Pharmacy Business. However, an extraordinary loss related to fire damage caused the bottom line to decrease.
Note : On April 1, 2020, the Company conducted a two-for-one stock split of common stock.
3
Net income per share has been calculated as if this stock split had taken place at the beginning of the fiscal year ended March 31, 2020.
1
Financial Highlights
Impact of Fire at a Contract Logistics Center
A fire at a contract logistics center in western Japan to which Nihon Generic outsources product warehousing operations damaged 34% of inventory.
Date and time of fire
Broke out around 8:50 a.m. November 29, 2021 Extinguished at 5:00 p.m. December 4, 2021 (Police/fire investigation is ongoing)
Damage
34% of inventory, 1.4 months of sales
Distribution has returned to normal, mainly through a logistics center in eastern Japan.
Impact on financial results
Extraordinary loss of 3.91 billion yen recorded as "loss on disaster" in Q3 this year.
All of the products damaged by the fire were covered by insurance, and the Company expects to record insurance claim income by the end of the current fiscal year. The insurance company is in the process of finalizing the insurance claim amount, but we will promptly make an announcement should matters requiring disclosure arise.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
NIHON CHOUZAI Co. Ltd. published this content on 31 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 January 2022 06:20:17 UTC.
NIHON CHOUZAI Co., Ltd is primarily engaged in the pharmacy business, the provision of staffing services, as well as the manufacture and sale of pharmaceutical products. The Company operates in three business segments. The Pharmacy segment is engaged in the operation of a chain of dispensing pharmacies. The Pharmaceutical Product Manufacturing and Distribution segment is engaged in the manufacture and nationwide sale of generic pharmaceutical products. The Healthcare Personnel Staffing Service segment is involved in the dispatching of pharmacists to various regional pharmacies.